Earlybird Health Closes €173 Million Second Fund for Healthtech Startups

Earlybird Health, a Germany-based venture capital firm, announced the closing of its second fund, amounting to €173 million (approximately $185 million). 

Earlybird Health Fund will predominantly invest in European companies from the early development stage to advanced technologies nearing regulatory approval and commercialisation. The Fund aims to invest in companies across healthcare sectors including digital health, diagnostics, medical devices, R&D tools, and biopharma – delivering robust and positive patient outcomes, regardless of the technology applied. It also complies with the Article 8 Fund criteria, per the EU’s Sustainable Finance Disclosure Regulation (SFDR).

Earlybird uses a proprietary in-house technology, Eagle Eye, for deal sourcing. Harnessing data aggregation and curation of multiple sources, the AI tool scouts new startups and gathers information for established entities. The tool increases deal flow from stealth mode companies to crossover financing rounds, offering market intelligence through competitor analyses and trend reports.

Biotechs currently in Earlybird's portfolio include Ariceum Therapeutics, Grey Wolf Therapeutics, ImCheck Therapeutics, Oculis and Priothera.